Years after the United States elected a president with the motto America First, we just pulled ahead in a race no one wants to win: the most deaths from the novel coronavirus. In order to limit casualties from a catastrophic second wave, states have enacted measures of differing severity, from shutting down some businesses to move severe shelter in place orders mandating citizens stay in their homes
Capping decades of research, a new study may offer a breakthrough in treatingdyskeratosis congenitaand other so-called telomere diseases, in which cells age prematurely. Using cells donated by patients with the disease, researchers at theDana-Farber/Boston Childrens Cancer and Blood Disorders Centeridentified several small molecules that appear to reverse this cellular aging process.Suneet Agarwal, the studys senior investigator, hopes at least one of these compounds will advance toward clinical trials. Findings werepublished Tuesday in the journal Cell Stem Cell
Given the debilitating impact of COVID-19 (Coronavirus) on the Canine Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Canine Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.
Six University of WisconsinMadison faculty have been elected to the American Academy of Arts and Sciences. Bioethicist R
GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe
Repotspedia.Com has added the newest research on Stem Cells Types, Technologies And Therapeutics Market, which offers a concise outline of the market valuation, industry size, SWOT analysis, revenue approximation, and therefore the regional outlook of this business vertical. The report exactly includes the key chances and difficulties looked by contenders of this industry and present the predominant serious setting and procedures authorized by the Stem Cells Types, Technologies And Therapeutics Market players. Request a sample Report of Stem Cells Types, Technologies And Therapeutics Market at: https://www.reportspedia.com/report/life-sciences/global-stem-cellstypes,-technologies-and-therapeutics-market-report-2019,-competitive-landscape,-trends-and-opportunities/29418 #request_sample As per the Stem Cells Types, Technologies And Therapeutics Market report, this industry is predicted to grow with a substantial returns by the top of the forecast duration, recording a profitable yearly growth within the upcoming years.
LOS ALTOS, CA / ACCESSWIRE / April 25, 2020 / Retrotope announced today that it received a "Study May Proceed" letter from US Food and Drug Administration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of RT001 in the treatment of PSP. In addition, the FDA provided useful guidance and suggestions for detailed design elements of the trial.
27 April 2020 Genome-edited human stem cells from diabetic patientshavebeen shown to successfully reverse diabetes in mice. Researchers at Washington University School of Medicine in St Louis, Missouri, used CRISPR/Cas9 to correct a genetic defect in human stem cells and then converted them into cells capable of producing insulin. When these edited insulin-producing cells were implanted into diabetic mice, they were able to effectively control blood sugar levels for six months
CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.
Cell conversion specialist Mogrify has announced a collaboration and licence agreement with US genomic medicine company Sangamo Therapeutics.
Recent Comments